WO2014046417A1 - Procédé de préparation d'agrégats de cellules souches du mésenchyme - Google Patents

Procédé de préparation d'agrégats de cellules souches du mésenchyme Download PDF

Info

Publication number
WO2014046417A1
WO2014046417A1 PCT/KR2013/008228 KR2013008228W WO2014046417A1 WO 2014046417 A1 WO2014046417 A1 WO 2014046417A1 KR 2013008228 W KR2013008228 W KR 2013008228W WO 2014046417 A1 WO2014046417 A1 WO 2014046417A1
Authority
WO
WIPO (PCT)
Prior art keywords
mesenchymal stem
medium
cells
stem cells
condition
Prior art date
Application number
PCT/KR2013/008228
Other languages
English (en)
Inventor
Yoon-Sun Yang
Won Il Oh
Hong Bae Jeon
JuEun HA
Soon-Jae Kwon
Original Assignee
Medipost Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medipost Co., Ltd. filed Critical Medipost Co., Ltd.
Publication of WO2014046417A1 publication Critical patent/WO2014046417A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
    • C12N2500/14—Calcium; Ca chelators; Calcitonin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture

Definitions

  • the present invention relates to a method for preparing mesenchymal stem cell aggregates.
  • stem cell is a generic name for undifferentiated cells obtained from respective tissues of embryos, fetuses and adults, which has the potential of differentiating into a various cell types. Stem cells are characterized by self- renewal, the ability to go through numerous cycles of cell division (while maintaining an undifferentiated state), and potency, the capacity to differentiate into specialized cell types in response to certain stimuli (environment), and even by plasticity, the ability to cross lineage barriers and adopt the expression profile and functional phenotypes of cells that are unique to other tissues.
  • Stem cells may be classified into pluripotent stem cells, multipotent stem cells and unipotent stem cells according to their potency.
  • Pluripotent stem cells have pluripotency to differentiate into any type of cells.
  • Embryonic stem cells (ES cells) and induced pluripotent stem cells (iPS cells) are representative of pluripotent stem cells.
  • adult stem cells show multipotency and/or unipotency. Among them are hematopoietic stem cells, mesenchymal stem cells, neural stem cells, etc.
  • iPS cells Induced pluripotent stem cells
  • iPS cells are a type of pluripotent stem cells artificially derived from differentiation-completed adult somatic cells by reprogramming.
  • iPS l cells may avoid the risk of immune rejection response because they are derived entirely from the patient, however, the risk of oncogenesis with iPS cells is still a problem to be solved.
  • mesenchymal stem cells are being promoted because they exhibit immunomodulatory effects and present no risk of oncogenesis.
  • Mesenchymal stem cells are multipotent stem cells that can differentiate into a variety of cell types, including adipocytes, osteocystes, chondrocytes, myocytes, neurocytes, myocardiocytes, hepatocytes, islet beta cells, vascular cells, etc., and are known to have the function of modulating immune responses.
  • Mesenchymal stem cells may be isolated from various tissues such as the bone marrow, umbilical cord blood, adipose tissue, etc., but are not sufficiently defined because cell surface markers are somewhat different from one another according to the origin from which the mesenchymal stem cells are derived. On the whole, if they can differentiate into osteoblasts, chondrocytes and myoblasts, have a spindle shaped morphology, and express the surface markers CD73(+), CD105(+), CD34(-) and CD45(-), the stem cells are defined as mesenchymal stem cells.
  • mesenchymal stem cells of different genetic origins and/or backgrounds do not significantly differ from one another in terms of their definition, i.e., that of a mesenchymal stem cell, but are typically different from each other in terms of in vivo activity. Further, when mesenchymal stem cells are used as exogenous cell therapeutics, a limited pool of mesenchymal stem cells does not allow many choices or available options, even in spite of low in vivo activity.
  • the minimum number of mesenchymal stem cells necessary for them to be used as a cell therapeutic in regenerative medicine and/or cell therapy is approximately 1 x 10 9 cells. In practice, the minimum number is further increased in consideration of experiments for setting proper conditions and determining criteria.
  • the supply of mesenchymal stem cells in such quantities from various origins requires at least ten in vitro passages. In this case, however, the cells become aged and deformed so that they may be unsuitable for use as cell therapeutics.
  • WOl 1/126264 discloses a method for preparing a highly active human mesenchymal stem cell aggregate.
  • WOl 1/126264 demonstrates that mesenchymal stem cell aggregates (also referred to 'mesenchymal stem cell mass') show good in vivo tissue regeneration and treatment efficacy, high in vivo viability, and good differentiation efficiency into tissue cells.
  • the present inventors have endeavored to study on the mesenchymal stem cell aggregates; and have found that the formation of mesenchymal stem cell aggregates and immunological properties of mesenchymal stem cell aggregates can be enhanced by culturing the mesenchymal stem cells under specific conditions before the cells initiate the formation of aggregates.
  • a method for preparing mesenchymal stem cell aggregates which comprises the steps of: (1) culturing mesenchymal stem cells in a medium containing calcium in a concentration of from 2.1 to 3.8 mM and magnesium in a concentration of from 1.0 to 3.0 mM under a hypoxic condition with a 2 to 5% of oxygen concentration; and (2) forming aggregates by culturing the mesenchymal stem cells thus obtained in a medium containing serum replacement instead of fetal bovine serum.
  • mesenchymal stem cell aggregates prepared by the method, which exhibit improved aggregate formation and immunological properties.
  • a cell therapeutic agent comprising the mesenchymal stem cell aggregates of the present invention.
  • the method for culturing mesenchymal stem cell aggregates according to the present invention can enhance the formation of mesenchymal stem cell aggregates and immunological properties by culturing the mesenchymal stem cells under specific conditions before the cells initiate the formation of aggregates.
  • FIGs. 1A and IB are graphs showing cell count folds relative to the seeded cell count at 7 days (upper) and cumulative cell counts until 21 days (lower) after umbilical cord blood-derived mesenchymal stem cells derived from two different sources (MSC #1 and #2) were cultured in a-MEM ranging in calcium concentration from 1.8 to 9.3 raM.
  • PI to P3 represent numbers of passage.
  • FIGs. 2A and 2B are graphs showing cell counts after umbilical cord blood- derived mesenchymal stem cells derived from two different sources (MSC #1 and #2) were cultured for 7 days in the presence of a total calcium concentration of from 1.8 to 3.6 mM (upper) and for 6 days in the presence of a total calcium concentration of from 1.8 mM to 4.4 mM (lower).
  • FIGs. 3A and 3B are graphs showing doubling times when umbilical cord blood-derived mesenchymal stem cells derived from two different sources (MSC #1 and #2) were cultured under various oxygen conditions (normal, 3% and 5%) (upper), and cumulative cell counts until 21 days after the umbilical cord blood-derived mesenchymal stem cells were cultured under the oxygen conditions (lower).
  • PI to P3 represent numbers of passage.
  • FIG. 4 shows doubling times (upper), and cumulative cell counts (lower) after umbilical cord blood-derived mesenchymal stem cells (MSC #1) were cultured in a typical condition (control), in an increased calcium condition (Ca 2+ ), in a hypoxic condition, and in a CMH condition.
  • MSC #1 umbilical cord blood-derived mesenchymal stem cells
  • P5 to P12 represent numbers of passage
  • the CMH condition means a combination of the calcium and magnesium addition condition and the hypoxic condition.
  • FIG. 5 shows cell viability (upper) and recovery rates (lower) 1 and 2 days after umbilical cord blood-derived mesenchymal stem cells were cultured in a typical condition (control), in a calcium addition condition (Ca ), in a hypoxic condition, and in a CMH condition.
  • FIGs. 6A and 6B show doubling times (upper), and cumulative cell counts (lower) after umbilical cord blood-derived mesenchymal stem cells (MSC #1 to #4) were cultured in a typical condition (control), and in a CMH condition.
  • PI to P9 represent numbers of passage.
  • FIG. 7 shows mRNA expression levels of the sternness markers Oct4 and nanog and the senescence marker P16 after umbilical cord blood-derived mesenchymal stem cells derived from two different sources (MSC #1 and #2) were cultured in a typical condition (control), in a calcium addition condition (Ca 2+ ), in a hypoxic condition, and in a CMH condition.
  • FIG. 8 shows photographs of umbilical cord blood-derived mesenchymal stem cells stained with SA-p-gal after passages in a typical condition (control) and in a CMH condition (upper), and a graph in which ⁇ -gal activity is plotted according to culture conditions after umbilical cord blood-derived mesenchymal stem cells were cultured in a typical condition (control), in a calcium addition condition (Ca 2+ ), in a hypoxic condition, and in a CMH condition (lower).
  • FIG. 9 shows photographs of umbilical cord blood-derived mesenchymal stem cells derived from two different sources (MSC #1 and #2) after the cells cultured in a typical condition (control) and in a CMH condition were induced to differentiate to cartilage and bone.
  • FIG. 10 shows graphs illustrating whether two different umbilical cord blood- derived mesenchymal stem cells (MSC #1 and #2) cultured in a typical condition (control) and in a CMH condition stimulate responder cells (A), wherein A, B and H represent responder cells, stimulator cells, and PHA, respectively.
  • FIG. 11 shows graphs of levels of PGE 2 (prostaglandin E 2 ) released from umbilical cord blood-derived mesenchymal stem cells (MSC #1 and #2) cultured in the conditions of FIG. 10.
  • PGE 2 prostaglandin E 2
  • FIG. 12 is a graph showing levels of Tsp-2 released from four different umbilical cord blood-derived mesenchymal stem cells (MSC #1 to #4) cultured for 24 hrs in a typical condition (control) and in a CMH condition.
  • MSC #1 to #4 umbilical cord blood-derived mesenchymal stem cells
  • FIG. 13 shows microscopic photographs of aggregates of umbilical cord blood- derived mesenchymal stem cells derived from two different sources (MSC #1 and #2) prepared by cutting the cells in a typical condition and in a CMH condition (3.6 mM Ca 2+ , 1.8 mM Mg 2+ and 3% 0 2 ) and forming aggregates by using a hanging drop method described in Example 9.
  • IK, 10K and 20K each indicates an aggregate prepared by using l x l O 3 , l x l O 4 and 2x 10 4 cells per 20 ⁇ , of medium, respectively.
  • FIG. 14 shows graphs illustrating immunogenicity of umbilical cord blood- derived mesenchymal stem cell aggregates prepared in accordance with the present invention.
  • Mesenchymal stem cells cultured in a typical condition and in a CMH condition and mesenchymal stem cell aggregates formed after cultured in a typical condition (I K, 1 OK and 20K) and in a CMH condition (I K, 1 OK and 20K) were used to determine whether or not responder cells (A) were stimulated by these samples.
  • a and H refer to responder cells and PHA-L, respectively.
  • FIG. 15 shows graphs illustrating immunosuppression of umbilical cord blood- derived mesenchymal stem cell aggregates prepared in accordance with the present invention.
  • Mesenchymal stem cells cultured in a typical condition and in a CMH condition, and mesenchymal stem cell aggregates formed after cultured in a typical condition (IK, 10K and 20K) and in a CMH condition (IK, 10K and 20K) were used to determine whether or not these samples show immunosuppression under immune response-induced condition (A+B), where responder cells (A) were allowed to react with stimulating cells (B).
  • A, B and H refer to responder cells, stimulating cells and PHA-L, respectively.
  • FIG. 16 shows graphs illustrating cytokine secretion of umbilical cord blood- derived mesenchymal stem cell aggregates, which demonstrate the amounts of Tsp-2 and VEGF secreted from mesenchymal stem cells cultured in a typical condition and in a CMH condition, and mesenchymal stem cell aggregates formed after cultured in a typical condition (I K, 10K and 20K) and in a CMH condition (I K, 10K and 20K).
  • the present invention provides a method for preparing mesenchymal stem cell aggregates, which comprises the steps of: (1 ) culturing mesenchymal stem cells in a medium containing calcium in a concentration of from 2.1 to 3.8 mM and magnesium in a concentration of from 1.0 to 3.0 mM under a hypoxic condition with a 2 to 5% of oxygen concentration; and (2) forming aggregates by culturing the mesenchymal stem cells thus obtained in a medium containing serum replacement instead of fetal bovine serum.
  • aggregate refers to a spherical stem cell aggregation formed by culturing stem cells, and used interchangeably with “stem cell mass” or “spheroid” in the art.
  • the culturing method of the present invention may be applied to mesenchymal stem cells of various origins.
  • mesenchymal stem cells useful in the present invention include those derived from umbilical cord blood, bone marrow, lipid, muscle, skin, amniotic fluid, umbilical cord, or teeth, but are not limited thereto.
  • the culturing method of the present invention is applied to umbilical cord blood-derived mesenchymal stem cells.
  • the mesenchymal stem cells to which the culturing method of the present invention can be applied may be derived from various subjects.
  • the mesenchymal stem cells useful in the present invention may be obtained from mammals including humans, but are not limited thereto.
  • mesenchymal stem cells of human origin are used.
  • Step (1) is characterized by culturing mesenchymal stem cells in a medium containing calcium in a concentration of from 2.1 to 3.8 mM and magnesium in a concentration of from 1.0 to 3.0 mM under a hypoxic condition with a 2 to 5% of oxygen concentration.
  • the culture medium may be prepared from a typical culture medium for stem cells by adjusting the concentrations of calcium and magnesium.
  • Examples of the typical culture medium include Dulbecco's modified eagle medium (DMEM), minimal essential medium (MEM), a-MEM, McCoys 5A medium, eagle's basal medium, CMRL (Connaught Medical Research Laboratory) medium, Glasgow minimal essential medium, Ham's F-12 medium, IMDM (Iscove's modified Dulbecco's medium), Leibovitz's L-15 medium, RPMI (Roswell Park Memorial Institute) 1640 medium, medium 199, and Hank's medium 199, but are not limited thereto.
  • DMEM Dulbecco's modified eagle medium
  • MEM minimal essential medium
  • MEM minimal essential medium
  • a-MEM McCoys 5A medium
  • eagle's basal medium eagle's basal medium
  • CMRL Connaught Medical Research Laboratory
  • Glasgow minimal essential medium Ham's F-12 medium
  • IMDM Iscove's modified Dulbecco's
  • the culture medium may or may not contain serum.
  • a serum replacement may be used, instead of serum, in the culture medium.
  • the culture medium contains 5 to 30% of fetal bovine serum (FBS). In another embodiment, the culture medium contains a serum replacement.
  • FBS fetal bovine serum
  • various growth factors in a human serum or a human platelet lysate including PDGF, TGF, IGF, and cytokines of a family of such proteins may be used as the serum replacement.
  • calcium functions to promote the proliferation of mesenchymal stem cells, with the suppression of immunogenicity and the stimulation of cytokine secretion.
  • calcium may be used in a concentration of from 2.1 to 3.8 mM in the medium, preferably in a concentration of from 3.3 to 3.8 mM, and more preferably in a concentration of approximately 3.6 mM.
  • calcium may be added in a concentration of from 0.3 to 2.0 mM, preferably in a concentration of from 1.5 to 2.0 mM, and more preferably in a concentration of approximately 1.8 mM because the medium already contains 1.8 mM of calcium.
  • the calcium concentration to be added to achieve the desired concentration necessary for implementing the culturing method of the present invention can be readily calculated in consideration of the calcium concentration of a medium itself, taken from among typical media.
  • magnesium is employed to prevent the precipitation of calcium.
  • Magnesium may be used in a concentration of from 1.0 to 3.0 mM in the medium, and preferably in a concentration of approximately 1.8 mM.
  • magnesium is present in a concentration of less than 1.0 mM in the culture medium, calcium is apt to precipitate.
  • a magnesium concentration higher than 3.0 mM in the culture medium is likely to block the formation of the extracellular matrix (ECM), interfere with the adherence of the cells to the bottom of the culture dish, thus rendering them susceptible to shear stress, and increase intracellular mineralization.
  • ECM extracellular matrix
  • magnesium when a-MEM is adopted as the culture medium, magnesium may be added in a concentration of from 0.2 to 2.2 mM, and preferably in a concentration of 1.0 mM because the medium already contains 0.8 mM of magnesium.
  • the magnesium concentration to be added to achieve the desired concentration necessary for implementing the culturing method of the present invention can be readily calculated in consideration of the magnesium concentration of a medium itself, taken from among typical media.
  • the culture medium according to a preferred embodiment of the present invention may be based on a-MEM supplemented with 5 to 30% of fetal bovine serum (FBS), 0.3 to 2.0 mM of calcium, and 0.2 to 2.2 mM of magnesium, thus calcium and magnesium amounting to a total of from 2.1 to 3.8 mM, and from 1.0 to 3.0 mM, respectively.
  • FBS fetal bovine serum
  • the hypoxic condition of Step (1) in accordance with the present invention as compared to a normoxic condition, efficiently promotes the proliferation of mesenchymal stem cells, with the suppression of immunogenicity and the stimulation of cytokine secretion.
  • the hypoxic condition is an atmosphere with an oxygen content of from 2 to 5%.
  • a problem with an oxygen concentration below 2% or over 5% is a significant decrease in the proliferation of mesenchymal stem cells.
  • mesenchymal stem cells are cultured in an atmosphere of approximately 3% of oxygen.
  • the hypoxic condition may be achieved by adjusting the oxygen concentration of a cell incubator.
  • an incubator may be purged with nitrogen (100%) or nitrogen/carbon dioxide (95%/5%) to adjust the normoxic atmosphere into a hypoxic atmosphere.
  • the oxygen concentration in an incubator may be monitored by an oxygen sensor installed on the incubator.
  • mesenchymal stem cells may be cultured in a conventional manner.
  • mesenchymal stem cells may be cultured in a three-dimensional bioreactor or spinner or a typical adherent culture vessel.
  • a synergistic effect can be obtained. That is, a combination of the concentration of calcium and magnesium and the hypoxic condition allows mesenchymal stem cells to proliferate more efficiently, with a higher improvement in the suppression of immunogenicity and the stimulation of cytokine secretion, compared to the individual conditions. For example, under the combined conditions, mesenchymal stem cells proliferate 1.5- to 5-fold further, with a 1- to 3- fold decrease in immunogenicity, and a 1.5- to 3-fold increase in cytokine secretion, compared to individual conditions.
  • the combined condition for the culturing method of the present invention is referred to as "CMH condition" (calcium + magnesium + hypoxic condition).
  • Step (2) is characterized by forming aggregates by culturing mesenchymal stem cells obtained in Step (1) in a medium containing serum replacement instead of fetal bovine serum.
  • Examples of culture medium which may be used for forming aggregates in Step (2) include Dulbecco's modified eagle medium (DMEM), minimal essential medium (MEM), a-MEM, McCoys 5A medium, eagle's basal medium, CMRL (Connaught Medical Research Laboratory) medium, Glasgow minimal essential medium, Ham's F-12 medium, IMDM (Iscove's modified Dulbecco's medium), Leibovitz's L-15 medium, RPMI (Roswell Park Memorial Institute) 1640 medium, Medium 199, and Hank's medium 199, but are not limited thereto.
  • DMEM Dulbecco's modified eagle medium
  • MEM minimal essential medium
  • MEM minimal essential medium
  • a-MEM McCoys 5A medium
  • eagle's basal medium eagle's basal medium
  • CMRL Connaught Medical Research Laboratory
  • Glasgow minimal essential medium Ham's F-12 medium
  • IMDM Iscove
  • the culture medium free of fetal bovine serum does not include basic fibroblast growth factor (bFGF) but may additionally contain a serum replacement.
  • the serum replacement may comprise serum albumin, transferrins, hemoglobin beta chains, etc. as a main ingredient.
  • the serum replacement may include serum albumin precursor, apolipoprotein A-I precursor, transthyretin precursor, serotransferrin precursor, antithrombin III, plasma retinol-binding protein (PRBP), serotransferrin, vitamin D- binding protein precursor, hemoglobin beta chain, anionic trypsin II precursor, alpha- 1 -antiproteinase, alpha-2-HS-glycoprotein precursor, etc.
  • any conventional serum replacement known in the art may be employed in the present invention, e.g., KnockOutTM SR (Invitrogen).
  • various growth factors in a human serum or a human platelet lysate including PDGF, TGF, IGF, and cytokines may be used.
  • the culture of the human mesenchymal stem cells to form the spherical cell aggregate may be carried out in a culture drop placed against gravity.
  • the spherical cell aggregate may be formed to include 300 to 30,000 cells per culture drop (approximately 20 ⁇ ), preferably 1 ,000 to 30,000 cells per culture drop, so as to obtain a spherical cell aggregate having a high therapeutic efficacy.
  • the culturing method of stem cells against gravity results in obtaining a number of stem cell aggregates having a uniform size, which enhance the therapeutic effectiveness.
  • the culture of the mesenchymal stem cells to form the aggregate may be carried out by suspension culture employing a low-attachment culture dish.
  • the aggregate may be formed by employing a three-dimensional bioreactor.
  • the mesenchymal stem cells may be cultured at room temperature, for example, 30 to 40 °C, preferably about 37 °C, for 12 to 72 hours under atmospheric condition with 5% C0 2 .
  • the produced aggregates may be separated by using a strainer.
  • the present invention provides mesenchymal stem cell aggregates prepared by the method.
  • the mesenchymal stem cell aggregates in accordance with the present invention have a dense and rigid structure, implying that aggregates can be easily formed owing to the increased expression of adhesive molecules present or inducible on the surface of the mesenchymal stem cells.
  • the mesenchymal stem cell aggregates in accordance with the present invention have reduced immunogenicity, improved immunosuppression and good secretion ability of cytokines (e.g., Tsp-2 and VEGF), and thus, may be used safely and effectively as a cell therapeutic agent.
  • cytokines e.g., Tsp-2 and VEGF
  • the present invention provides a cell therapeutic agent comprising the mesenchymal stem cell aggregates.
  • the cell therapeutic agent of the present invention finds applications in the regeneration or protection of adipocytes, osteocytes, chondrocytes, myocytes, neurocytes, cardiomyocytes, hepatocytes, islet beta cells, vascular cells, or pneumocytes.
  • the cell therapeutic agent of the present invention is useful for one selected from the group consisting of the treatment of pulmonary diseases; the suppression or treatment of lung disease- induced inflammation; the regeneration of pulmonary tissues; and the suppression of pulmonary fibrosis. Particularly, it can be used to suppress or improve pulmonary disease-induced inflammation and fibrosis.
  • the cell therapeutic agent of the present invention can be applied to the therapy of cardiovascular diseases or the regeneration of cartilage. Moreover, the cell therapeutic agent of the present invention can reduce immune responses, immune cell penetration, or immunogenicity; improve immunomodulative functions; and suppress inflammatory reactions. Also, the cell therapeutic agent of the present invention is applied to therapy of autoimmune diseases, or graft- vs-host diseases.
  • the present invention provides a use of the cell a cell therapeutic agent comprising the mesenchymal stem cell aggregates in the manufacture of a medicament for: (1) regeneration or protection of adipocytes, osteocytes, chondrocytes, myocytes, neurocytes, cardiomyocytes, hepatocytes, islet beta cells, vascular cells, or pneumocytes; (2) one selected from the group consisting of treatment of pulmonary diseases, suppression or treatment of lung disease-induced inflammation, regeneration of pulmonary tissues, and suppression of pulmonary fibrosis; (3) regeneration of cartilage; or (4) therapy of autoimmune diseases, or graft-vs-host diseases.
  • human cord blood-derived mesenchymal stem cells were obtained from Medipost Co. Ltd., Korea.
  • the cells may be prepared by collecting umbilical cord blood, isolating mesenchymal stem cells from umbilical cord blood, and culturing the mesenchymal stem cells, as illustrated below.
  • Umbilical cord blood may be collected from the umbilical vein which is expelled out of the uterus either while the placenta remains within the uterus after normal spontaneous vaginal delivery or once the placenta has been expelled from the uterus after cesarean section.
  • the umbilical vein which is expelled from the uterus and by which the newborn is connected to the placenta must be aseptically treated before collecting umbilical cord blood therefrom.
  • Umbilical cord blood is withdrawn from the umbilical vein into a bag containing an anticoagulant through a syringe.
  • Monocytes are separated by centrifuging the collected umbilical cord blood and washed several times to remove impurities therefrom. Then, the monocytes are seeded at a proper density into a culture vessel and allowed to grow with the formation of a single layer.
  • Mesenchymal stem cells are morphologically homogeneous and grow while forming colonies comprising spindle-shaped cells, as observed under a phase-contrast microscope. Then, the cells are cultured with passage upon confluence until a necessary number of cells are obtained.
  • EXAMPLE 1 Proliferative Capacity of Umbilical Cord Blood-Derived Mesenchymal Stem Cells According to Calcium Concentration
  • umbilical cord blood-derived mesenchymal stem cells were cultured in the presence of various concentrations of calcium.
  • Umbilical cord blood-derived mesenchymal stem cells (MSC #1 and #2) which had been collected after delivery with the informed consent of different mothers and stored in a frozen state were thawed, and cultured at 37 °C in a-MEM (Invitrogen, USA) supplemented with 10% FBS under a 5% C0 2 condition in an incubator (hypoxic/C0 2 incubator, Thermo Scientific #3131). When the cells were grown to 80 to 90% confluency, they were separated into single cells by treatment with trypsin.
  • a-MEM supplied with 10% FBS; containing 1.8 raM calcium and 0.8 mM magnesium
  • various concentrations (0 mM, 1.5 mM, 3 mM, 4.5 mM, 6 mM, and 7.5 mM) of calcium were added so that the calcium concentrations of the medium was adjusted into: 1.8 mM, 3.3 mM, 4.8 mM, 6.3 mM, 7.8 mM, and 9.3 mM.
  • the mesenchymal stem cells were inoculated at a density of 5,000 cells/cm into the media.
  • magnesium was added in a concentration of 1 mM to each medium (containing a total magnesium concentration of 1.8 mM).
  • FIGs. 1A and IB are graphs showing cell count folds relative to the seeded cell count at 7 days (upper) and cumulative cell counts until 21 days (lower) after umbilical cord blood- derived mesenchymal stem cells derived from two different sources (MSC #1 and #2) were cultured in ct-MEM to which calcium was further added in various concentrations of from 0 to 7.5 mM.
  • the proliferative capacity of the cells peaked when calcium was further added in a concentration of 1.5 mM (a total calcium concentration of 3.3 mM), which was also observed in the same pattern over passages.
  • the proliferative capacity was gradually decreased.
  • FIGs. 2 A and 2B are graphs showing cell counts after umbilical cord blood-derived mesenchymal stem cells derived from two different sources (MSC #1 and #2) were cultured for 7 days in the presence of a total calcium concentration of 1.8 mM, 2.1 mM, 2.4 mM, 2.7 mM, 3.0 mM, 3.3 mM and 3.6 mM (upper), and for 6 days in the presence of a total calcium concentration of 1.8 mM, 3.4 mM, 3.6 mM, 3.8 mM, 4.0 mM, 4.2 mM, and 4.4 mM (lower).
  • the proliferative capacity increased over an added calcium concentration range from 0 to 1.8 mM (total concentrations of from 1.8 to 3.6 mM in media), and then started to decrease when the added calcium concentration exceeded 1.8 mM (a total calcium concentration of 3.6 mM in media). From these results, it is understood that the optimal calcium concentration for allowing the maximal proliferation of mesenchymal stem cells is 3.6 mM in a medium.
  • EXAMPLE 2 Proliferative Capacity of Umbilical Cord Blood-Derived Mesenchymal Stem Cells According to Oxygen Concentration
  • umbilical cord blood-derived mesenchymal stem cells were cultured in the presence of various concentrations of oxygen.
  • umbilical cord blood-derived mesenchymal stem cells were cultured in the same manner as in Example 1 under 3% or 5% of oxygen, or under a normoxic (oxygen level 21% in air) condition, with the exception that neither calcium nor magnesium was further added to a 10% FBS-supplemented a-MEM.
  • the results are given in FIGs. 3A and 3B.
  • FIGs. 3A and 3B The results are given in FIGs.
  • 3A and 3B are graphs showing times it took for the cells to double in number when umbilical cord blood-derived mesenchymal stem cells derived from two different sources (MSC #1 and #2) were cultured under various oxygen conditions (normal, 3% and 5%) after 1, 2 and 3 rounds of passage (upper), and cumulative cell counts until 21 days after the umbilical cord blood-derived mesenchymal stem cells were cultured under the oxygen conditions (lower).
  • the proliferative capacity was measured to be higher under the hypoxic conditions than the normoxic conditions, although there were differences between batches. Particularly, the proliferative capacity peaked at an oxygen level of 3%, which was observed in the same pattern for the cells which had been cultured with many rounds of passage. In addition, the cells were examined for proliferative capacity under further fractioned oxygen conditions to a maximum of 5%. An oxygen level of from 2 to 5% was preferred (data not shown).
  • EXAMPLE 3 Proliferative Capacity of Umbilical Cord Blood-Derived Mesenchymal Stem Cells According to Combination of Calcium (inclusive of Magnesium) and Oxygen Conditions
  • the cells were cultured in a typical condition (control), in the presence of externally added calcium (inclusive of magnesium), in a hypoxic condition, and in an externally added calcium (inclusive of magnesium)/hypoxic condition (hereinafter referred to as "CMH").
  • CMH calcium/hypoxic condition
  • the media contained calcium and magnesium at total concentrations of 3.6 and 1.8 mM, respectively (1.8 mM calcium and 1 mM magnesium additionally added).
  • the hypoxic condition was set forth at an oxygen level of 3%.
  • the cells were cultured in a manner similar to that of Example 1. After 5 passages (P5) in the typical condition, the mesenchymal stem cells were cultured with 7 rounds of passages (PI 2) in the CMH condition at regular intervals of 7 days between passages.
  • FIG. 4 shows doubling times (day) of the cells (upper), and cumulative cell counts (lower) after passages under the conditions.
  • the proliferative capacity of the cells was significantly increased when they were cultured in the CMH condition, compared to the hypoxic condition or the calcium addition condition. This effect was observed in the same pattern over many rounds of passage. Experiments with various batches of cells showed similar results although there were differences to some degree. Thus, these results demonstrate that the CMH condition of the present invention is very effective for proliferating umbilical cord blood-derived mesenchymal stem cells.
  • umbilical cord blood-derived mesenchymal stem cells were cultured in a typical condition (control), in a hypoxic condition (3%), in an increased calcium condition (1.8 mM; a total calcium level of 3.6 mM in a medium), and in a CMH condition (3% 0 2 + 1.8 mM calcium added + 1 mM magnesium added), detached from culture vessels, and washed three times with and suspended in a fundamental medium (cc-MEM). While being maintained at room temperature, the cell suspensions were examined for viability and recovery rate with time.
  • Cell viability was expressed as a percentage of live cells to dead cells after the cells collected and suspended in a fundamental medium were stained with trypan blue and total cells including live cells stained blue in a predetermined volume (10 to 20 ⁇ ,) of the suspension were counted using a hemocytometer. The recovery rate was expressed as a percentage of live cell counts post-culture to pre-culture.
  • FIG. 5 shows cell viability (upper) and recovery rates (lower) one and two days after umbilical cord blood-derived mesenchymal stem cells were cultured in the conditions.
  • the cells were observed to exhibit higher viability and recovery rate when they were cultured in the hypoxic condition or the increased calcium condition than in the typical condition, and even higher viability and recovery rate when they were cultured in the CMH condition.
  • the same results were obtained with umbilical cord blood-derived mesenchymal stem cells derived from different sources although there were some differences therebetween to some degree.
  • MSC #1 to #4 Mesenchymal stem cells were cultured with passage in a typical condition and in the CMH condition, and examined for proliferative capacity. The results are given in FIGs. 6A and 6B which show doubling time (upper) and cumulative cell counts (lower).
  • the CMH condition significantly reduced the doubling time, an index for cell proliferation, over many rounds of passage, compared to the control.
  • a much greater number of mesenchymal stem cells even though derived from the same source, were obtained in the CMH condition.
  • the same results were obtained from experiments with different umbilical cord blood-derived mesenchymal stem cells although there was a difference therebetween to some degree.
  • These data indicate that the CMH condition induces mesenchymal stem cells to proliferate with better efficiency.
  • an even greater number of mesenchymal stem cells were produced when the CMH condition was applied to an initial passage of umbilical cord blood-derived mesenchymal stem cells.
  • EXAMPLE 5 Assay for Stemness and Senescence of Umbilical Cord Blood-Derived Mesenchymal Stem Cells According to Culture Condition To examine why the CMH condition improves the proliferation of umbilical cord blood-derived mesenchymal stem cells, their stemness and senescence, which are associated with the proliferation of stem cells, were assayed.
  • Real-time PCR was carried out on the cDNA using primers specific for the stemness markers Oct4 and nanog, the senescence marker PI 6, and GADPH.
  • the PCR started with denaturation at 95 °C for 10 min, and was performed with 30 cycles of 95 °C for 10 sec, 62 °C for 30 sec, and 72 °C for 10 sec in a LightCycler 480 Real-Time PCR System instrument (Roche).
  • RNA obtained by the RT-PCR were normalized to that of GAPDH before the expression levels of RNA for each marker in the cells cultured in the typical condition and the CMH condition were compared (relative analysis, ddCT method).
  • FIG. 7 shows mRNA expression levels of two different umbilical cord blood-derived mesenchymal stem cells (MSC #1 and #2).
  • the expression levels of the sternness markers Oct4 and nanog were higher in the umbilical cord blood-derived mesenchymal stem cells cultured in the CMH condition than in a typical condition (control) and than in individual conditions.
  • the senescence marker PI 6 showed an inverse expression pattern to that of Oct4.
  • Umbilical cord blood-derived mesenchymal stem cells were cultured in a typical condition and in a CMH condition as in Example 3, with 7 to 8 passages. After removal of the media, the cells were washed once with PBS, and incubated at room temperature for 3 to 5 min with 1 mL of a lx fixation solution (Cell Signaling Technology). The fixation solution was removed from the cells which were then washed twice with 2 mL of PBS.
  • a lx fixation solution Cell Signaling Technology
  • the cells were incubated for 2 to 24 hrs with 1 mL of a dye solution for ⁇ -galactosidase (Cell Signaling Technology) in a 37 °C incubator. After removal of the dye solution therefrom, the cells were washed with 1 mL of PBS, and the resulting stained senescent cells were counted under the inverted microscope ECLIPSE TE2000-U (Nikon Co., Kanagawa, Japan).
  • a dye solution for ⁇ -galactosidase Cell Signaling Technology
  • FIG. 8 shows microphotographs of cells after staining with SA-P-gal (upper), and graphs of SA-P-gal activity (lower).
  • the SA-P-gal activity was determined by calculating the ratio of stained cells to total cells counted on a photograph taken at 40- to 100-fold magnification.
  • the progression of senescence in the mesenchymal stem cells was retarded further in the CMH condition than in the calcium addition condition or the hypoxic condition, and much further than in the typical condition.
  • mesenchymal stem cells were assayed for differentiation potential and marker expression by chondrogenic induction and osteogenic induction.
  • Umbilical cord blood-derived mesenchymal stem cells obtained from two different sources were cultured in a typical condition (control) and in a CMH condition, as in Example 3, before they were induced to differentiate into cartilage and bone, as follows. Then, differentiation into cartilage and bone was evaluated using a staining method.
  • telomeres were placed in a population of 2 to 2.5x 10 s cells in a 15 mL conical tube, and centrifuged to give a cell pellet. It was washed with D-PBS and suspended in 200 to 250 ⁇ , of a differentiation medium [high glucose DMEM (Gibco, cat#. 11995), 10 ng/mL TGFp-3 (Sigma, cat#. T5425, 2 ⁇ ), 500 ng/mL BMP-6 (R&D, cat#. 507-BP, 20 ⁇ g), 50 ⁇ g/mL ascorbic acid (Sigma, cat#. A8960), 50 mg/mL (1 : 100) ITSTM+ Premix (BD, cat#.
  • a differentiation medium [high glucose DMEM (Gibco, cat#. 11995), 10 ng/mL TGFp-3 (Sigma, cat#. T5425, 2 ⁇ ), 500 ng/mL BMP-6 (R&D, cat#. 507-BP,
  • the cells were centrifuged, washed with PBS, and fixed at room temperature for 0.5 to 1 hr in 4% paraformaldehyde. Subsequently, the cells were washed two or three times with distilled water, and prepared into sections (4 to 5 ⁇ thick) using a cryosection method. The sections were immersed for 3 to 5 min in 95% ethanol, and washed twice with water. After being stained for 7 min with 0.1% safranin O, the cells were washed twice with 70% ethanol, once with 70% ethanol, twice with 95% ethanol, once with 95% ethanol, and twice with 100% ethanol, immersed for 3 min in a xylene substrate solution, and dried. Thereafter, the stained cells were covered with a lipid-soluble mounting solution and observed. The chondrogenic induction was evaluated by comparing the color (violet), the size of differentiated pellets, and the lacuna structure formed.
  • the cells were plated at a density 500 to 1000 cells/well into 6-well plates, and 2 to 4 days later, the medium was substituted with an osteogenic induction medium ( ⁇ -glycerol phosphate 2.1604 g, L-ascorbic acid-2- phosphate 0.012805 g, dexamethasoneAJVAB 0.6 mg, gentamycin (10 mg mL) 5 mL and FBS 100 mL in 1 L of a-MEM).
  • the cells were cultured for 2 to 3 weeks with the differentiation medium substituted with a fresh one every three days.
  • the chondrogenic induction was evaluated by an ALP staining method.
  • the differentiated cells were washed twice with PBS and incubated for 30 to 45 sec in a fixation solution (40% acetone). They were washed again two or three times with distilled water and incubated for 30 min with an alkaline staining solution (Fast violet B salt) in a dark place. Then, the cells were washed twice with distilled water, and treated for 10 to 20 sec with Mayer's hematoxylin solution. After removal of the staining solution therefrom, the cells were washed with tap water, dried, covered with a lipid-soluble mounting solution, and observed. Because osteoblasts are stained dark brown due to the activation of intracellular alkaline phosphatase, the chondrogenic induction was evaluated by the degree of staining.
  • FIGs. 9A and 9B The results are given in FIGs. 9A and 9B. As can be seen in FIGs. 9A and 9B, there were no significant differences in chondrogenic induction and osteogenic induction between the mesenchymal stem cells cultured in the typical condition and in the CMH condition.
  • Umbilical cord blood-derived mesenchymal stem cells cultured in a typical condition and in the CMH condition were trypsinized, and washed three times with PBS containing 2% FBS. They were reacted with the hematopoietic cell-associated antigens CD34 and CD45, both conjugated with FITC (fluorescein isothiocyanate), the immunomodulation-associated antigen CD73 conjugated with PE (phycoerythrin), and the angiogenesis-associated antigen CD 105 conjugated with PE.
  • FITC fluorescein isothiocyanate
  • PE immunomodulation-associated antigen CD73 conjugated with PE
  • angiogenesis-associated antigen CD 105 conjugated with PE conjugated with PE.
  • the cells were additionally marked with a secondary antibody (IgG-FITC; Jackson ImmunoResearch, West Grove, PA, USA) in a manner similar to Western blotting, followed by detecting the signal of the secondary antibody using FACS to ratios of the cells expressing the markers to total cells. After the reaction, the signals were analyzed using a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA, USA), and the software CELLQUEST.
  • a secondary antibody IgG-FITC; Jackson ImmunoResearch, West Grove, PA, USA
  • EXAMPLE 7 Comparison of Immunogenicity and Immunosuppression of Umbilical Cord Blood-Derived Mesenchymal Stem Cells According to Culture Condition
  • MLR mixed lymphocyte reaction
  • umbilical cord blood-derived mesenchymal stem cells cultured in the presence of 10 ⁇ g/mL mitomycin C (Sigma- Aldrich, St Louis, MO, USA) in a typical condition and in a CMH condition were separately seeded at a density of 2> ⁇ 10 4 cells/well into 96-well plates, responder cells (peripheral blood monocytes (expressed as "A”); ALLCELLS, Emeryville, CA) at a density of 1 > ⁇ 10 5 cells/well, and stimulator cells (unrelated peripheral blood monocytes (expressed as "B”); ALLCELLS, Emeryville, CA) at a density of 1 * 10 5 cells/well.
  • mitomycin C Sigma- Aldrich, St Louis, MO, USA
  • peripheral blood monocytes treated with 10 ⁇ g/mL PHA-L (expressed as "H”; Roche Diagnostics GmbH, Mannheim, Germany) were added at a density of l x lO 5 cells/well to 96-well plates.
  • PHA-L peripheral blood monocytes treated with 10 ⁇ g/mL
  • each of the responder cells and the stimulator cells were added at a density of 1 ⁇ 10 5 cells/well.
  • mesenchymal stem cells were incubated with peripheral blood monocytes, PHA-L-stimulated peripheral blood monocytes, or a combination of the responder cells and the stimulator cells, each monocyte being used at a density of 1 x 10 5 cells, for 5 days, and the proliferation and colony formation of the responder cells were observed under a microscope.
  • the cells were treated with BrdU (BD Bioscience, San Jose, CA, USA) so that levels of the DNA newly synthesized for the previous 24 hrs in the responder cells were determined by measuring absorbance at 370 nm on a VERSAmaxTM microplate reader (Molecular Devices Co., Sunnyvale, CA, USA). The results are shown in FIG. 10.
  • the proliferation was induced in the PHA-L(H)-stimulated unrelated peripheral blood monocytes (A+H) whereas umbilical cord blood-derived mesenchymal stem cells did not stimulate the responder cells, thus resulting in no induction of cell proliferation (hUCB-MSC+A).
  • the umbilical cord blood-derived mesenchymal stem cells were observed to have greater inhibitory effects on the proliferation of the responder cells when they were cultured in the CMH condition than in the typical condition.
  • the umbilical cord blood-derived mesenchymal stem cells cultured in the CMH condition were observed to suppress the proliferation of the responding peripheral blood monocytes more greatly than did those cultured in the typical condition. Similar results were obtained with umbilical cord blood-derived mesenchymal stem cells obtained from different sources although there was a difference to some, but slight degree. These data demonstrate that a CMH culture condition is advantageous over typical conditions in terms of the suppression of immunogenicity.
  • PGE 2 prostaglandin E 2
  • an immunosuppressant released therefrom was analyzed using a PGE2 ELISA kit (Cayman, Ann Arbor, MI, USA) according to the protocol of the manufacturer. The cultures from the MLR were used as specimens.
  • Standards necessary for ELISA assay were prepared to have a maximum density of 1,000 pg/mL, with a minimum density of 7.8 pg/mL serially half-diluted from the maximum.
  • Each of the standards and the culture supernatants of the test group was added in an amount of 50 ⁇ to each well of PGE 2 capture antibody- coated plates.
  • 50 LL of the PGE 2 AchE tracer and 50 of a primary antibody were added to each well, followed by incubation at 4 °C for 18 hrs.
  • the plates were washed five times with a wash buffer, and 200 of Ellman's reagent (included within the kit), was added to each well, followed by the addition of 5 of the tracer per well.
  • the plates were incubated for 60 to 90 min in a dark condition, and absorbance was read at 450 nm.
  • EXAMPLE 8 In Vitro Assay for Ability of Umbilical Cord Blood- Derived Mesenchymal Stem Cells to Release Cytokines According to Culture Condition Effects of culture conditions on the ability of umbilical cord blood-derived mesenchymal stem cells to release cytokines were assayed by measuring Tsp-2 released during the differentiation of the umbilical cord blood-derived mesenchymal stem cells into chondrocytes.
  • Umbilical cord blood-derived mesenchymal stem cells were cultured in a typical condition (control) and in a CMH condition in the same manner as in Example 3. When reaching 80 to 90% confluency, they were detached by treatment with trypsin. After centrifugation, the cell pellets were washed with high glucose DMEM containing 40 ⁇ g/mL L-proline, 0.6 dexamethasone, 50 ⁇ g/mL ascorbic acid, and 100 sodium pyruvate, to completely remove FBS from the cells.
  • the umbilical cord blood-derived mesenchymal stem cell pellets obtained again by centrifugation were suspended at a density of 2.0x 10 5 cells/400 iL, and placed in an aliquot of 400 in 15 mL conical tubes. After centrifugation at 550*g for 5 min, the tubes were so very loosely closed. The tubes were incubated for 24 hrs while being placed upright in a rack. Once a pellet was formed, the supernatant was collected and analyzed for the level of Tsp-2 using a Tsp-2 assay kit (R&D systems, USA).
  • Tsp-2 is a factor accounting for the titer of umbilical cord blood-derived mesenchymal stem cells for use as a cartilage regenerating agent. Cells that released a higher level of Tsp-2 were evaluated to regenerate cartilage more effectively. As is apparent from the data of FIG. 12, all of four different umbilical cord blood-derived mesenchymal stem cells released higher levels of Tsp-2 in the CMH condition than in the typical condition.
  • the data obtained above indicate that the umbilical cord blood-derived mesenchymal stem cells cultured in the CMH condition have excellent potential of differentiating into chondrocytes and are thus useful as a cartilage regenerating agent.
  • EXAMPLE 9 Preparation of Aggregates of Umbilical Cord Blood- derived Mesenchymal Stem Cells Cultured in a CMH Condition
  • Mesenchymal stem cells derived from umbilical cord blood were cultured in a CMH condition, and then allowed to form aggregates by using a hanging drop method to obtain umbilical cord blood-derived mesenchymal stem cell aggregates.
  • human umbilical cord blood-derived mesenchymal stem cells derived from two different sources (MSC #1 and #2) stored in a frozen state were thawed, and cultured at 37 °C in a-MEM medium (Invitrogen, USA) supplemented with 10% FBS under a 5% C0 2 condition in a Forma Series II Water- Jacketed C0 2 incubator (Thermo Scientific Inc.). When the cells were grown to 80 to 90% confluency, they were separated into single cells by treatment with trypsin.
  • the mesenchymal stem cells thus obtained were inoculated in a concentration ranging from 5,000 to 8,000 cells/cm 2 into a-MEM medium (supplemented with 10% FBS) where 1.8 mM calcium and 1 mM magnesium were further added thereto.
  • the cells were cultured in a 3% (v/v) oxygen (hypoxic) condition, with passages upon 80 to 90% confluency.
  • an aggregate formation medium was prepared by adding 20% KnockOutTM SR (Invitrogen), 0.1 nmol/L ⁇ -mercaptoethanol, 1 % non-essential amino acid (Invitrogen) and 50 ⁇ g/mL gentamycin to DMEM/F-12 medium (Invitrogen).
  • the mesenchymal stem cells were separated into single cells by treating with trypsin.
  • the cells were counted, inoculated at l x lO 3 cells/20 ⁇ , (IK), l lO 4 cells/20 ⁇ , (10K) and 2> ⁇ 10 4 cells/20 ⁇ , (20K) into the media, and then the mesenchymal stem cells were placed on a 100 i>(mm) plate with 20 ⁇ , drops. Subsequently, PBS was added to the plate in order to prevent the drops from drying, and the plate was turned upside down so that the cells were cultured against gravity to prepare aggregates. The cells were cultured in an incubator at 37 °C for 2 days under atmospheric condition with 5% C0 2 .
  • COMPARATIVE EXAMPLE 1 Preparation of Aggregates of Umbilical Cord Blood-derived Mesenchymal Stem Cells Cultured in a Typical Condition
  • Example 9 The procedures of Example 9 were repeated, except that neither calcium nor magnesium were added, and the mesenchymal stem cells were cultured in a 21 % (v/v) oxygen (normoxia) condition instead of a hypoxic condition, to prepare umbilical cord blood-derived mesenchymal stem cell aggregates.
  • EXPERIMENTAL EXAMPLE 1 Comparison of the Degree of Formation of Umbilical Cord Blood-derived Mesenchymal Stem Cell Aggregates Depending on Culture Conditions
  • Example 9 The umbilical cord blood-derived mesenchymal stem cell aggregates prepared in Example 9 and Comparative Example 1 were observed using an ECLIPSE TE2000-U microscope (Nikon Co., Kanagawa, Japan).
  • EXPERIMENTAL EXAMPLE 2 Comparison of Immunogenicity of Umbilical Cord Blood-derived Mesenchymal Stem Cell Aggregates Depending on Culture Conditions
  • Example 9 and Comparative Example 1 For negative control, umbilical cord blood-derived mesenchymal stem cells cultured (2* 10 4 cells) in the presence of 10 g/mL mitomycin C (Sigma-Aldrich, St Louis, MO, USA) in a typical condition and in a CMH condition, and umbilical cord blood-derived mesenchymal stem cell aggregates (IK, 10K and 20K) prepared Example 9 and Comparative Example 1 were prepared. In case of the aggregates prepared in Example 9 and Comparative Example 1, the concentrations of the cells equally adjusted by adding 20, 2 and 1 aggregates per well for IK, 10K and 20K samples, respectively.
  • mitomycin C Sigma-Aldrich, St Louis, MO, USA
  • l x lO 5 cells of responder cells peripheral blood mononuclear cells (expressed as “A”); ALLCELLS, Emeryville, CA) were treated with 10 ⁇ g/mL PHA-L (leucoagglutinin) (expressed as "H”; Roche Diagnostics GmbH, Mannheim, Germany) to prepare a positive control.
  • a test group was prepared by treating the negative control with 1 * 10 5 cells of peripheral blood mononuclear cells (A).
  • the negative control, positive control and test group were incubated for 5 days in 96-well plates, and the proliferation and colony formation of the responder cells were observed under a microscope.
  • the cells were treated with BrdU (BD Bioscience, San Jose, CA, USA) so that levels of the newly synthesized DNA of the responder cells for 24 hrs were determined by measuring absorbance at 370 nm on a VERSAmaxTM microplate reader (Molecular Devices Co., Sunnyvale, CA, USA).
  • FIG. 14 The results are shown in FIG. 14. As can be seen from FIG. 14, the proliferation was induced in the PHA-L-stimulated peripheral blood mononuclear cells (A+H), whereas umbilical cord blood-derived mesenchymal stem cells and aggregates thereof did not stimulate the responder cells, thus resulting in no induction of cell proliferation.
  • the aggregates (10K and 20K) were observed to have less immunogenicity as compared to mesenchymal stem cells, and particularly, the aggregates which were cultured in the CMH condition showed more reduced immunogenicity than the aggregates which were cultured in the typical condition. Also, it was found that there exists an inverse relationship between the immunogenicity among the aggregates and the size of the aggregates.
  • mitomycin C Sigma-Aldrich, St Louis, MO, USA
  • the concentrations of the cells were made equal by adding 20, 2 and 1 aggregates per well for I , 10K and 20K samples, respectively.
  • a mixture of l x lO 5 cells of responder cells (A) and l x lO 5 cells of stimulating cells (B), and responder cells (A) were treated with PHA-L (H) prepared as a positive control.
  • a test group was prepared by treating the negative control with l x lO 5 cells of responder cells (A) and l x lO 5 cells of stimulating cells (B).
  • the negative control, positive control and test group were incubated for 5 days in 96-well plates, and the proliferation and colony formation of the responder cells were observed under a microscope.
  • the cells were treated with BrdU (BD Bioscience, San Jose, CA, USA) so that levels of the newly synthesized DNA of the responder cells for 24 hrs were determined by measuring absorbance at 370 nm on a VERSAmaxTM microplate reader (Molecular Devices Co., Sunnyvale, CA, USA).
  • umbilical cord blood-derived mesenchymal stem cell aggregates cultured in a typical and in a CHM condition were assayed by measuring Tsp-2 and VEGF, which are known as cytokines to be associated with cartilage regeneration therapy and the treatment of pulmonary diseases, respectively.
  • a cell adhesion material e.g., plasma or corona
  • mitomycin C Sigma- Aldrich, St Louis, MO, USA
  • Example 9 the concentrations of the cells were made equal by adding 300, 30 and 15 aggregates per well for IK, 10K and 20K samples, respectively. After centrifugation, the supernatant was collected and analyzed for the level of each cytokine using Tsp-2 and VEGF assay kits (R&D systems, USA). The results are shown in FIG. 16. As can be seen from FIG. 16, umbilical cord blood-derived mesenchymal stem cell aggregates cultured in the CMH condition released higher levels of cytokines as compared to those cultured in the typical condition. Also, the difference between these two conditions markedly became larger as the size of the aggregates increased.
  • the data obtained above indicate that the umbilical cord blood-derived mesenchymal stem cell aggregates cultured in a CMH condition is advantageous over those cultured in a typical condition in terms of their effectiveness in cartilage regeneration and treatment of pulmonary diseases.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un procédé de préparation d'agrégats de cellules souches du mésenchyme, le procédé comprenant les étapes suivantes : (1) la culture de cellules souches du mésenchyme dans un milieu contenant du calcium à une concentration de 2,1 mM à 3,8 mM et du magnésium à une concentration de 1,0 mM à 3,0 mM, dans des conditions hypoxiques avec une concentration en oxygène de 2 % à 5 % ; et (2) la formation d'agrégats par la culture des cellules souches du mésenchyme ainsi obtenues dans un milieu contenant un substitut de sérum à la place du sérum de bovin fœtal. Les agrégats de cellules souches du mésenchyme préparées par le procédé susmentionné possèdent une structure dense et rigide, de meilleures propriétés immunologiques et d'excellentes capacités de sécrétion de cytokines, et peuvent donc être utilisés en toute innocuité et de manière efficace comme agent thérapeutique cellulaire.
PCT/KR2013/008228 2012-09-20 2013-09-11 Procédé de préparation d'agrégats de cellules souches du mésenchyme WO2014046417A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2012-0104726 2012-09-20
KR1020120104726A KR20140038236A (ko) 2012-09-20 2012-09-20 간엽줄기세포 응집체의 제조 방법

Publications (1)

Publication Number Publication Date
WO2014046417A1 true WO2014046417A1 (fr) 2014-03-27

Family

ID=50341662

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2013/008228 WO2014046417A1 (fr) 2012-09-20 2013-09-11 Procédé de préparation d'agrégats de cellules souches du mésenchyme

Country Status (2)

Country Link
KR (1) KR20140038236A (fr)
WO (1) WO2014046417A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3041930A4 (fr) * 2013-09-05 2017-01-18 Medipost Co., Ltd. Procédé de culture de cellules souches mésenchymateuses selon la taille des cellules
CN107287157A (zh) * 2017-05-18 2017-10-24 舟山医院 无血清培养人牙龈间充质干细胞的方法
WO2018053618A1 (fr) * 2016-09-21 2018-03-29 University Health Network Procédés de culture de cellules stromales mésenchymateuses
EP3305306A1 (fr) * 2016-10-04 2018-04-11 Dr. Sarah Prinzessin von Isenburg Compositions comprenant des concentrations réglables de facteurs de croissance dérivés de sérum sanguin et de support de caillot en situation d'hypoxie et leurs procédés de production
CN108486035A (zh) * 2018-03-26 2018-09-04 西北大学 一种三维类器官的液滴培养方法
EP3299023A4 (fr) * 2015-05-21 2019-03-20 Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences Cellule souche mésenchymateuse cultivée en hypoxie et utilisation de celle-ci
CN110227058A (zh) * 2019-06-10 2019-09-13 北京恒峰铭成生物科技有限公司 多效因子组合物及其制备方法和应用
CN114457010A (zh) * 2022-02-17 2022-05-10 湖南南华爱世普林生物技术有限公司 一种干细胞衍生品及其制备方法和应用
CN115851590A (zh) * 2023-03-02 2023-03-28 天津永泰生命科技有限公司 一种规模化提纯干细胞衍生物的方法及应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102009081B1 (ko) * 2016-12-23 2019-08-09 주식회사 인스코비 발모 촉진을 위한 생체 식립용 임플란트

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100080836A1 (en) * 2007-05-04 2010-04-01 Ascendia Ab Method and means for culturing osteoblastic cells
US20100261276A1 (en) * 2007-07-20 2010-10-14 Dongguk University Industry-Academic Cooperation Foundation Method For The Preparation Of Dermal Papilla Tissue Employing Mesenchymal Stem Cells
KR20110112164A (ko) * 2010-04-05 2011-10-12 서울대학교병원 인간 줄기세포의 활성을 증가시키는 방법
KR20120008223A (ko) * 2010-07-16 2012-01-30 주식회사 알앤엘바이오 양막유래 중간엽 줄기세포 배양을 위한 배지조성물 및 이를 이용한 양막유래 중간엽 줄기세포의 배양방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100080836A1 (en) * 2007-05-04 2010-04-01 Ascendia Ab Method and means for culturing osteoblastic cells
US20100261276A1 (en) * 2007-07-20 2010-10-14 Dongguk University Industry-Academic Cooperation Foundation Method For The Preparation Of Dermal Papilla Tissue Employing Mesenchymal Stem Cells
KR20110112164A (ko) * 2010-04-05 2011-10-12 서울대학교병원 인간 줄기세포의 활성을 증가시키는 방법
KR20120008223A (ko) * 2010-07-16 2012-01-30 주식회사 알앤엘바이오 양막유래 중간엽 줄기세포 배양을 위한 배지조성물 및 이를 이용한 양막유래 중간엽 줄기세포의 배양방법

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARKWAY, B. D. ET AL.: "Enhanced chondrogenic differentiation of human bone marrow-derived mesenchymal stem cells in low oxygen environment micropellet cultures", CELL TRANSPLANT, vol. 19, no. 1, 2010, pages 29 - 42 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3041930A4 (fr) * 2013-09-05 2017-01-18 Medipost Co., Ltd. Procédé de culture de cellules souches mésenchymateuses selon la taille des cellules
US10150950B2 (en) 2013-09-05 2018-12-11 Medipost Co., Ltd Method for culturing mesenchymal stem cells according to cell size
EP3299023A4 (fr) * 2015-05-21 2019-03-20 Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences Cellule souche mésenchymateuse cultivée en hypoxie et utilisation de celle-ci
WO2018053618A1 (fr) * 2016-09-21 2018-03-29 University Health Network Procédés de culture de cellules stromales mésenchymateuses
EP3305306A1 (fr) * 2016-10-04 2018-04-11 Dr. Sarah Prinzessin von Isenburg Compositions comprenant des concentrations réglables de facteurs de croissance dérivés de sérum sanguin et de support de caillot en situation d'hypoxie et leurs procédés de production
WO2018065092A1 (fr) * 2016-10-04 2018-04-12 Prinzessin Von Isenburg Sarah Compositions comportant des concentrations ajustables de facteurs de croissance dérivés du sérum sanguin et de milieu conditionné par l'hypoxie des caillots et leurs procédés de production
CN107287157A (zh) * 2017-05-18 2017-10-24 舟山医院 无血清培养人牙龈间充质干细胞的方法
CN108486035A (zh) * 2018-03-26 2018-09-04 西北大学 一种三维类器官的液滴培养方法
CN108486035B (zh) * 2018-03-26 2021-11-26 西北大学 一种三维类器官的液滴培养方法
CN110227058A (zh) * 2019-06-10 2019-09-13 北京恒峰铭成生物科技有限公司 多效因子组合物及其制备方法和应用
CN114457010A (zh) * 2022-02-17 2022-05-10 湖南南华爱世普林生物技术有限公司 一种干细胞衍生品及其制备方法和应用
CN115851590A (zh) * 2023-03-02 2023-03-28 天津永泰生命科技有限公司 一种规模化提纯干细胞衍生物的方法及应用

Also Published As

Publication number Publication date
KR20140038236A (ko) 2014-03-28

Similar Documents

Publication Publication Date Title
US11332715B2 (en) Method for culturing mesenchymal stem cells
WO2014046417A1 (fr) Procédé de préparation d'agrégats de cellules souches du mésenchyme
TWI698527B (zh) 利用血管母細胞產生間葉基質細胞之方法
Hegab et al. Isolation and characterization of murine multipotent lung stem cells
US20100330047A1 (en) Mesenchymal Stem Cells Grown Under Hypoxic Conditions: Compositions, Methods and Uses Therefor
KR20080056302A (ko) 태반 유래 줄기세포로부터 생산된 희소돌기 아교세포
JP5431146B2 (ja) 免疫学的寛容および調節性前駆細胞
CN114540266A (zh) 用于治疗用途的岩藻糖基化细胞的制备和冷冻干燥
AU2014315919B2 (en) Method for culturing mesenchymal stem cells according to cell size
WO2010056341A2 (fr) Compositions et procédés pour la réparation tissulaire
JP5388297B2 (ja) アディポクラスター
CN107427536B (zh) 用于刺激细胞增殖和提供fgf2同种型的生物活性混合物的方法和组合物
WO2011068792A2 (fr) Compositions et procédés pour la fabrication et l'utilisation de cellules souches mésenchymateuses de moelle osseuse et de cellules progénitrices érythroïdes
WO2017012226A1 (fr) Cellules souches mésenchymateuses, procédé d'amplification clonogénique associé, procédé de séparation associé et utilisations associées
EP3680324A1 (fr) Cellules souches émanant de jeunes porcs et leur procédé de préparation
WO2020190672A1 (fr) Exosomes dérivés de cardiomyocytes induisant la régénération de tissu cardiaque endommagé
WO2021227573A1 (fr) Milieu de culture exempt de xeno et procédé de multiplication de cellules souches mésenchymateuses au moyen de celui-ci
WO2022092169A1 (fr) Composition ostéogénique et utilisation associée

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13839101

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC, FORM 1205A DATED 02-07-2015

122 Ep: pct application non-entry in european phase

Ref document number: 13839101

Country of ref document: EP

Kind code of ref document: A1